FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118482016> ?p ?o ?g. }

• W3118482016 abstract "Objective: Daprodustat is a novel oral agent in treating anemia of chronic kidney disease (CKD), and several clinical trials have been conducted to compare daprodustat with recombinant human erythropoietin (rhEPO) or placebo. Our systematic review aimed to investigate the efficacy and safety of daprodustat for anemia treatment in both dialysis-dependent (DD) and non-dialysis-dependent (NDD) patients. Methods: Six databases were searched for randomized controlled trials (RCTs) reporting daprodustat vs. rhEPO or placebo for anemia patients in CKD. The outcome indicators were focused on hemoglobin (Hb), ferritin, transferrin saturation (TSAT), total iron-binding capacity (TIBC), vascular endothelial growth factor (VEGF), and serious adverse events (SAEs). Results: Eight eligible studies with 1,516 participants were included. For both NDD and DD patients, changes in Hb levels from baseline were significantly higher in daprodustat group than that in the placebo (mean difference (MD) = 1.73, [95% confidence interval (CI), 0.34 to 3.12], p = 0.01; MD = 1.88, [95% CI, 0.68 to 3.09], p = 0.002; respectively), and there was no significant difference between daprodustat and rhEPO group (MD = 0.05, [95% CI, −0.49 to 0.59], p = 0.86; MD = 0.12, [95% CI, −0.28 to 0.52], p = 0.55; respectively). The indexes of iron metabolism were improved significantly in the daprodustat group compared to placebo- or rhEPO-treated patients, while there was no similar change in terms of TSAT for DD patients. Furthermore, no trend of increasing plasma VEGF was observed in daprodustat-treated subjects. As for safety, there was no significant difference in the incidence of SAEs between daprodustat and placebo treatment, while the incidence of SAEs in the daprodustat group was significantly lower than that in the rhEPO group. Conclusion: Daprodustat was efficacious and well tolerated for anemia in both NDD and DD patients in the short term based on current RCTs. And daprodustat may become an effective alternative for treatment of anemia with CKD. Since the application of daprodustat is still under exploration, future researches should consider the limitations of our study to evaluate the value of daprodustat." @default.
• W3118482016 created "2021-01-18" @default.
• W3118482016 creator A5002477430 @default.
• W3118482016 creator A5009265134 @default.
• W3118482016 creator A5016556055 @default.
• W3118482016 creator A5025734672 @default.
• W3118482016 creator A5032959348 @default.
• W3118482016 creator A5064500840 @default.
• W3118482016 creator A5083412151 @default.
• W3118482016 creator A5087320814 @default.
• W3118482016 date "2021-01-12" @default.
• W3118482016 modified "2023-10-14" @default.
• W3118482016 title "Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis" @default.
• W3118482016 cites W1964685535 @default.
• W3118482016 cites W1965845267 @default.
• W3118482016 cites W1991047577 @default.
• W3118482016 cites W1991304993 @default.
• W3118482016 cites W1998943227 @default.
• W3118482016 cites W2007553857 @default.
• W3118482016 cites W2007919022 @default.
• W3118482016 cites W2010157705 @default.
• W3118482016 cites W2018814956 @default.
• W3118482016 cites W2023289992 @default.
• W3118482016 cites W2024229944 @default.
• W3118482016 cites W2042212143 @default.
• W3118482016 cites W2042960850 @default.
• W3118482016 cites W2060277684 @default.
• W3118482016 cites W2072299843 @default.
• W3118482016 cites W2086913408 @default.
• W3118482016 cites W2087098834 @default.
• W3118482016 cites W2087830638 @default.
• W3118482016 cites W2088964670 @default.
• W3118482016 cites W2097697450 @default.
• W3118482016 cites W2098124630 @default.
• W3118482016 cites W2102237016 @default.
• W3118482016 cites W2104116785 @default.
• W3118482016 cites W2106855201 @default.
• W3118482016 cites W2116377721 @default.
• W3118482016 cites W2126806779 @default.
• W3118482016 cites W2130304025 @default.
• W3118482016 cites W2134487085 @default.
• W3118482016 cites W2137321538 @default.
• W3118482016 cites W2147160899 @default.
• W3118482016 cites W2150095076 @default.
• W3118482016 cites W2152183263 @default.
• W3118482016 cites W2170052125 @default.
• W3118482016 cites W2170066453 @default.
• W3118482016 cites W2177863951 @default.
• W3118482016 cites W2187754395 @default.
• W3118482016 cites W2204627976 @default.
• W3118482016 cites W2206481924 @default.
• W3118482016 cites W2268447664 @default.
• W3118482016 cites W2272875085 @default.
• W3118482016 cites W2317666770 @default.
• W3118482016 cites W2562262017 @default.
• W3118482016 cites W2593244426 @default.
• W3118482016 cites W2756339342 @default.
• W3118482016 cites W2767787764 @default.
• W3118482016 cites W2790701104 @default.
• W3118482016 cites W2799655697 @default.
• W3118482016 cites W2887185662 @default.
• W3118482016 cites W2891817334 @default.
• W3118482016 cites W2961921650 @default.
• W3118482016 cites W2970670654 @default.
• W3118482016 cites W2970684805 @default.
• W3118482016 cites W2977682063 @default.
• W3118482016 cites W2980991992 @default.
• W3118482016 cites W4294215472 @default.
• W3118482016 doi "https://doi.org/10.3389/fphar.2020.573645" @default.
• W3118482016 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7883598" @default.
• W3118482016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33597868" @default.
• W3118482016 hasPublicationYear "2021" @default.
• W3118482016 type Work @default.
• W3118482016 sameAs 3118482016 @default.
• W3118482016 citedByCount "12" @default.
• W3118482016 countsByYear W31184820162021 @default.
• W3118482016 countsByYear W31184820162022 @default.
• W3118482016 countsByYear W31184820162023 @default.
• W3118482016 crossrefType "journal-article" @default.
• W3118482016 hasAuthorship W3118482016A5002477430 @default.
• W3118482016 hasAuthorship W3118482016A5009265134 @default.
• W3118482016 hasAuthorship W3118482016A5016556055 @default.
• W3118482016 hasAuthorship W3118482016A5025734672 @default.
• W3118482016 hasAuthorship W3118482016A5032959348 @default.
• W3118482016 hasAuthorship W3118482016A5064500840 @default.
• W3118482016 hasAuthorship W3118482016A5083412151 @default.
• W3118482016 hasAuthorship W3118482016A5087320814 @default.
• W3118482016 hasBestOaLocation W31184820161 @default.
• W3118482016 hasConcept C126322002 @default.
• W3118482016 hasConcept C142724271 @default.
• W3118482016 hasConcept C153852466 @default.
• W3118482016 hasConcept C168563851 @default.
• W3118482016 hasConcept C197934379 @default.
• W3118482016 hasConcept C204787440 @default.
• W3118482016 hasConcept C27081682 @default.
• W3118482016 hasConcept C2777417653 @default.
• W3118482016 hasConcept C2778248108 @default.
• W3118482016 hasConcept C2778319317 @default.
• W3118482016 hasConcept C2778534260 @default.
• W3118482016 hasConcept C2778653478 @default.

• next